Abstract
Background/aimsTo evaluate the efficacy and safety of individualised 2.0 mg intravitreal aflibercept retreatment for diabetic macular oedema (DME) through the fifth year of management.MethodsThis is a phase IV, 2-year, open-label...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have